Long-term Recorlev Found Safe, Effective for Endogenous Cushing’s
Long-term treatment with Recorlev (levoketoconazole) safely leads to sustained reductions in cortisol levels, disease signs and symptoms, and improvements in quality of life in adults with endogenous Cushing’s syndrome, according to nearly two years of data from the Phase 3 SONICS trial. Treatment benefits were generally maintained or deepened…